MAPK7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Images
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Alternative names
BMK 1 kinase, BMK-1, Big MAP kinase 1, EC 2.7.11.24, ERK-4, Extracellular signal-regulated kinase 5, MAP kinase 7, MAPK 7, MK07_HUMAN, Mitogen-activated protein kinase 7, OTTHUMP00000065906, OTTHUMP00000065907, PRKM 7, PROTEIN KINASE, MITOGEN-ACTIVATED, 7
What's included?
Recommended products
MAPK7 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
Key facts
- Cell type
HeLa
- Species or organism
Human
- Tissue
Cervix
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon4.
- Disease
Adenocarcinoma
- Concentration
Properties
- Gene name
MAPK7
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing, Western blot
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 2 US: 2
- Adherent/suspension
Adherent
- Gender
Female
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate short-term storage conditions
-20°C
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
ERK5 also known as big MAP kinase 1 (BMK1) is an enzyme that functions as a protein-serine/threonine kinase within the MAP kinase family. It has a molecular weight of approximately 120 kDa. ERK5 is expressed in various tissues including the brain heart and lungs with notable expression in endothelial cells. The protein plays a mechanical role in signal transduction processes which it achieves by transmitting signals from extracellular sources to the cellular nucleus facilitating the regulation of gene expression.
- Biological function summary
ERK5 influences cellular functions through its role in promoting cell proliferation and differentiation. It serves as part of a signaling complex that includes the MAP kinase kinase 5 (MEK5). This interaction allows ERK5 to phosphorylate and subsequently activate target substrates such as transcription factors promoting cellular responses necessary for development and survival. ERK5 also plays a role in the response to oxidative stress which contributes to its impact on survival pathways and cellular stress responses.
- Pathways
ERK5 acts within the MAPK signaling cascade and is linked to the ERK/MAPK pathway and the phosphoinositide 3-kinase (PI3K) pathway. Within these pathways ERK5 interacts with other MAP kinases and regulatory proteins such as Ras and Raf contributing to a wide range of cellular processes including growth migration and survival. Through these interactions ERK5 influences cellular dynamics and mediates responses to growth factors and stress stimuli.
- Associated diseases and disorders
Abnormal activity of ERK5 has been implicated in various conditions including cardiovascular disease and cancer. Elevated ERK5 signaling can promote tumor progression and metastasis in certain cancers by enhancing tumor cell proliferation and survival. In cardiovascular disorders ERK5 interacts with proteins like calcium/calmodulin-dependent protein kinase II (CaMKII) influencing pathological cardiac remodeling and hypertrophy. These associations highlight ERK5's impact on disease mechanisms and highlight its potential as a therapeutic target.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human MAPK7 (ERK5) knockout HeLa cell lysate (ab258042)
Lane 1: Wild-type HeLa cell lysate (20μg)
Lane 2: MAPK7 knockout HeLa cell lysate (20μg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-ERK5 antibody [EP791Y] ab40809 observed at 115 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-ERK5 antibody [EP791Y] ab40809 Rabbit monoclonal [EP791Y] to ERK5 was shown to specifically react with ERK5 in wild-type HeLa cells in western blot. Loss of signal was observed when knockout cell line Human MAPK7 (ERK5) knockout HeLa cell line ab265508 (knockout cell lysate ab258042) was used. Wild-type and ERK5 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-ERK5 antibody [EP791Y] ab40809 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-ERK5 antibody [EP791Y] (Anti-ERK5 antibody [EP791Y] ab40809) at 1/1000 dilution
Lane 1: Wild-type HeLa cell lysate at 20 µg
Lane 2: MAPK7 knockout HeLa cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 88 kDa
Observed band size: 115 kDa
Sanger Sequencing - Human MAPK7 (ERK5) knockout HeLa cell lysate (ab258042)
Homozygous: 1 bp insertion in exon4
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com